Effects of dronabinol on morphine-induced dopamine-related behavioral effects in animals
Article first published online: 27 JUL 2012
Copyright © 2012 Wiley Periodicals, Inc.
Volume 66, Issue 11, pages 931–937, November 2012
How to Cite
Mori, T., Shibasaki, M., Abe, M., Udagawa, Y. and Suzuki, T. (2012), Effects of dronabinol on morphine-induced dopamine-related behavioral effects in animals. Synapse, 66: 931–937. doi: 10.1002/syn.21586
- Issue published online: 12 SEP 2012
- Article first published online: 27 JUL 2012
- Accepted manuscript online: 18 JUL 2012 04:19AM EST
- Manuscript Accepted: 10 JUL 2012
- Manuscript Revised: 6 JUL 2012
- Manuscript Received: 15 FEB 2012
- Grant-in-Aid from the Ministry of Education, Culture, Sports, Science
- Technology of Japan, Ministry of Health, Labour and Welfare of Japan
- rewarding effects;
The present study examined the effects of dronabinol, a United States FDA-approved synthetic cannabinoid receptor agonist, on morphine (a prototypic μ-opioid receptor agonist)-induced dopamine-related behaviors in animals. Dronabinol suppressed the rewarding effects of morphine in rats and its emetic effects in ferrets. Furthermore, the morphine-induced increase in dopamine release from the nucleus accumbens was significantly attenuated by dronabinol, which indicated that the suppressive effects of dronabinol on morphine-induced behaviors are at least in part mediated by regulation of the dopaminergic system. Since cannabinoid receptor agonists have been shown to enhance the antinociceptive effects of morphine, the use of dronabinol as an adjuvant could be useful for preventing the adverse effects of μ-opioid receptor agonists when used to control pain. Synapse 66:931–937, 2012. © 2012 Wiley Periodicals, Inc.